Marie-Anne van Stam1,2, Henk G van der Poel3, Jochem R N van der Voort van Zyp4, Corinne N Tillier3, Simon Horenblas1,3, Neil K Aaronson2, J L H Ruud Bosch1. 1. Department of, Urology, University Medical Center Utrecht, Utrecht, The Netherlands. 2. Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 3. Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 4. Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Abstract
OBJECTIVES: To assess the accuracy of patients' perceptions of the risks associated with localised prostate cancer treatments (radical prostatectomy [RP], radiotherapy [RT], and active surveillance [AS]), and to identify correlates of misperceptions. PATIENTS AND METHODS: We used baseline data (questionnaires completed after treatment information was provided but before treatment) of 426 patients with newly diagnosed localised prostate cancer who participated (87% response rate) in a prospective, longitudinal, multicentre study. Patients' pretreatment perceptions of differences in adverse outcomes of treatments were compared to those based on the literature. We used univariate and multivariate linear regression to identify correlates of misperceptions. RESULTS: About two-thirds (68%, n = 211) of the patients did not understand that the risk of disease recurrence is comparable between RP and RT. More than half of the patients did not comprehend that RP patients are at greater risk of urinary incontinence (65%, n = 202) and erectile dysfunction (61%, n = 190), and less at risk of bowel problems (53%, n = 211) compared to RT patients. Many patients overestimated the risk of requiring definitive treatment following AS (45%, n = 157) and did not understand that mortality rates following AS, RP, and RT are comparable (80%, n = 333). Consulting a radiotherapist or a clinical nurse specialist was positively associated with, and emotional distress was negatively associated with, better understanding of the risks (P < 0.05), although effect sizes were small. CONCLUSION: Prior to choosing treatment, most patients with prostate cancer poorly understood the differences in treatment risks. Greater efforts should be made to better understand why these misperceptions occur and, most importantly, how they can be corrected.
OBJECTIVES: To assess the accuracy of patients' perceptions of the risks associated with localised prostate cancer treatments (radical prostatectomy [RP], radiotherapy [RT], and active surveillance [AS]), and to identify correlates of misperceptions. PATIENTS AND METHODS: We used baseline data (questionnaires completed after treatment information was provided but before treatment) of 426 patients with newly diagnosed localised prostate cancer who participated (87% response rate) in a prospective, longitudinal, multicentre study. Patients' pretreatment perceptions of differences in adverse outcomes of treatments were compared to those based on the literature. We used univariate and multivariate linear regression to identify correlates of misperceptions. RESULTS: About two-thirds (68%, n = 211) of the patients did not understand that the risk of disease recurrence is comparable between RP and RT. More than half of the patients did not comprehend that RP patients are at greater risk of urinary incontinence (65%, n = 202) and erectile dysfunction (61%, n = 190), and less at risk of bowel problems (53%, n = 211) compared to RT patients. Many patients overestimated the risk of requiring definitive treatment following AS (45%, n = 157) and did not understand that mortality rates following AS, RP, and RT are comparable (80%, n = 333). Consulting a radiotherapist or a clinical nurse specialist was positively associated with, and emotional distress was negatively associated with, better understanding of the risks (P < 0.05), although effect sizes were small. CONCLUSION: Prior to choosing treatment, most patients with prostate cancer poorly understood the differences in treatment risks. Greater efforts should be made to better understand why these misperceptions occur and, most importantly, how they can be corrected.
Authors: Maarten Cuypers; Hoda H M Al-Itejawi; Cornelia F van Uden-Kraan; Peep F M Stalmeier; Romy E D Lamers; Inge M van Oort; Diederik M Somford; Reindert Jeroen A van Moorselaar; Irma M Verdonck-de Leeuw; Lonneke V van de Poll-Franse; Julia J van Tol-Geerdink; Marieke de Vries Journal: J Cancer Educ Date: 2020-12 Impact factor: 2.037
Authors: Nynikka R Palmer; Janet K Shim; Celia P Kaplan; Dean Schillinger; Sarah D Blaschko; Benjamin N Breyer; Rena J Pasick Journal: BMJ Open Date: 2020-08-05 Impact factor: 2.692
Authors: Maarten Cuypers; Romy E D Lamers; Paul J M Kil; Lonneke V van de Poll-Franse; Marieke de Vries Journal: Support Care Cancer Date: 2018-05-12 Impact factor: 3.603
Authors: Ruben D Vromans; Steffen C Pauws; Nadine Bol; Lonneke V van de Poll-Franse; Emiel J Krahmer Journal: BMC Med Inform Decis Mak Date: 2020-10-27 Impact factor: 2.796